Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or responded to previous treatment (refractory). Epcoritamab, a bispecific antibody, binds to two different types of receptors (proteins present on the cell surface) at the same time. The two receptors that epcoritamab binds to are called CD3 and CD20. CD3 is found on T cells, which are important cells of the immune system that help fight cancer and infections. CD20 is found on the surface of most types of aggressive B-cell non-Hodgkin lymphoma cells. By binding to both CD3 and CD20, epcoritamab brings the two cells close together so the T cells can fight and kill the lymphoma B cells. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, binds to a protein on B cells, a type of white blood cell from which the lymphoma developed. By doing this it decreases the ability of the lymphoma B cells to survive and grow. Ibrutinib may also improve the health (or fitness) of T cells thus making epcoritamab safer and/or more effective.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Jeden z typów agresywnego chłoniaka B-komórkowego (rozpoznany w badaniu mikroskopowym): rozlany chłoniak dużych komórek B, wysokozłośliwy chłoniak B-komórkowy, pierwotny chłoniak śródpiersiowy, chłoniak folikularny trzeciego stopnia lub chłoniak, który przekształcił się z mniej złośliwego typu
- •Wcześniejsze leczenie chemioterapią (antracyklinami) połączone z immunoterapią (lekiem przeciwko CD20)
- •Co najmniej 2 poprzednie leczenia systemowe lub co najmniej 1 leczenie dla pacjentów wysokiego ryzyka, którzy nie mogą otrzymać terapii CAR-T
- •Wiek co najmniej 18 lat
- •Jeśli pacjent otrzymywał wcześniej lek BTK, musiał go przerywać z powodu progresji choroby, a nie z powodu nietolerancji
- •Co najmniej 100 dni od przeszczepu macierzystych komórek hematopoezy (jeśli pacjent je otrzymywał)
- •Co najmniej 30 dni od terapii CAR-T (jeśli pacjent ją otrzymywał)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
University of Minnesota/Masonic Cancer Center
Minneapolis, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
VCU Massey Comprehensive Cancer Center
Richmond, United States
Trial contact
The Ohio State University Comprehensive Cancer Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.